A Novel Therapeutics for Pandemic & Epidemic Flu

流行病的新疗法

• 批准号: 6946426
• 负责人: Fang Fang
• 金额: $ 50万
• 依托单位: NEXBIO, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-15 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6946426
• 关键词: antiviral agents; cell line; chimeric proteins; communicable disease control; cytotoxicity; drug design /synthesis /production; influenza; intermolecular interaction; polymerase chain reaction; protease inhibitor; protein engineering; protein purification; recombinant proteins; serine proteinases; transfection /expression vector

DESCRIPTION (provided by applicant): Broad-spectrum therapeutics for influenza are critically needed to address the problem of influenza pandemics, a major threat to the public health globally. We have proposed studies that aim at generating a novel class of fusion proteins capable of blocking infections by all strains of influenza viruses. Specifically, the fusion protein is composed of a protease inhibitor that inhibits activation of all influenza viruses and an anchoring domain that helps to enrich the drug and prolong the drug retention on the respiratory epithelium. In the proposed phase I study, we will generate this proteinase inhibitor and its fusion proteins, compare their functional activities in vitro and choose the best construct for phase II study.

描述（由申请人提供）：迫切需要针对流感的广谱疗法来解决流感大流感的问题，这是对全球公共卫生的主要威胁。我们提出的研究旨在产生一种新型的融合蛋白，能够阻止所有流感病毒菌株的感染。具体而言，融合蛋白是由蛋白酶抑制剂组成的，该蛋白酶抑制剂抑制所有流感病毒的激活和一个锚定结构域，有助于富集药物并延长药物在呼吸上皮上的保留。在拟议的I期研究中，我们将生成该蛋白酶抑制剂及其融合蛋白，在体外比较其功能活性，并选择II期研究的最佳结构。